Quality Manager (GMP)

Job Description

Position Summary :

The Quality Manager (GMP) will be responsible for performing and managing day-to-day activities surrounding manufacture, testing and disposition for clinical study material. This will play a key role in overseeing all quality-related aspects of our outsourced manufacturing processes. This position is responsible for ensuring that products meet internal quality standards and comply with applicable regulatory requirements (e.g., FDA, EMA, GMP). As a liaison between the company and our contract manufacturing organization (CMO), the QA Manager will manage quality systems, review and approve batch records, handle deviations, and ensure proper documentation practices.

Key Responsibilities :

• Review of key manufacturing deliverables including MBRs, EBRs, Specifications, CoAs, Change Controls, Deviations, etc.
• Support management of External Vendor qualifications, including facilitation and / or execution of Vendor Audits primarily supporting manufacturing operations.
• Assist with management of Quality Investigations.
• Creation, implementation, administration of cross-functional UPB Quality Systems.
• Author and / or facilitate authoring and review of QMS documents across functional areas (including SOPs, Forms, Quality Investigations, etc.).
• Coordinate ongoing QMS training including organization and archival of associated documentation.
• Perform quality trends analysis and reports. Ability to analyze data to recommend continual improvements opportunities.

Qualifications :

About Upstream Bio :

Upstream Bio is a public company based in Waltham, MA.

We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Our team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.